What's new

Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Date of authorisation: 04/04/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Date of authorisation: 04/04/2022, Revision: 7, Status: Authorised

Feb 24, 2025 - 17:31
 0
Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Date of authorisation: 04/04/2022, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Date of authorisation: 04/04/2022, Revision: 7, Status: Authorised
Read More

Tags:

Previous Article

Ex-CDER chief Patrizia Cavazzoni becomes Pfizer’s chief medical officer

Next Article

List of medicinal products under additional monitoring

Related Posts

Orphan designation: Rilzabrutinib Treatment of autoimmune haemolytic anaemia, 16/01/2025 Positive

Orphan designation: Rilzabrutinib Treatment of autoimmu...

Feb 20, 2025  0

Human medicines European public assessment report (EPAR): Kinpeygo, budesonide, Date of authorisation: 15/07/2022, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025  0

Human medicines European public assessment report (EPAR): Cibinqo, abrocitinib, Date of authorisation: 09/12/2021, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 17, 2025  0